StemRIM
Stock Price Chart
2026/10/07 19:11 UpdatedPrice Trend
2026/10/07 19:11 UpdatedPrice & Trading Details
2026/10/07 19:11 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | |
|---|---|---|
| Income Statement | ||
| Revenue | ¥23M | ¥2,350M |
| Gross Profit | - | - |
| Operating Income | -¥1,981M | ¥142M |
| Pretax Income | -¥1,946M | ¥170M |
| Net Income | -¥1,948M | ¥168M |
| EPS | -¥32.92 | ¥2.69 |
| Operating Margin | -8,620.68% | 6.06% |
| Balance Sheet | ||
| Total Assets | ¥9,597M | ¥10,706M |
| Total Equity | ¥9,405M | ¥10,370M |
| Total Liabilities | ¥192M | ¥336M |
| Cash | ¥8,880M | ¥10,218M |
| Interest-bearing Debt | ¥4M | ¥1M |
| Equity Ratio | 97.99% | 96.86% |
| D/E Ratio | 0.00 | 0.00 |
| Cash Flow | ||
| Operating CF | -¥1,405M | ¥1,135M |
| Investing CF | -¥0M | -¥0M |
| Financing CF | ¥113M | ¥203M |
| Free CF | -¥1,405M | ¥1,135M |
| Efficiency | ||
| ROE | -20.72% | 1.62% |
| ROA | -20.30% | 1.57% |
Latest IR Information
-
Notice of US Patent Registration for Stem Cell Gene Therapy Technology for Recessive Dystrophic Epidermolysis Bullosa (Development Code: SR-GT1)
A patent for a treatment for recessive dystrophic epidermolysis bullosa is expected to be registered in the US. SR-GT1 is a therapy using autologous mesenchymal stem cells with introduction of a normal type VII collagen gene to achieve long-term engraftment....
Read more -
Notice of Appointment of Directors Candidates, Audit & Supervisory Board Members and Substitute Audit & Supervisory Board Members
Decision to expand to five director candidates and appoint three Audit & Supervisory Board candidates and one substitute Audit & Supervisory Board candidate. New director candidate Yoshida Iida added to the list, new Audit & Supervisory Board candidate Waada Okudaira...
Read more -
Notice on Stock Acquisition Rights as Stock Options for Directors, Employees, and External Collaborators
Introduces a stock option system granting stock acquisition rights at no cost to executive officers, employees, and external collaborators. The grant is up to 8,000 units, 1 unit equals 100 shares, and the exercise price is the closing price on...
Read more -
Announcement of patent registration in Korea for Redosemtide's use in cartilage diseases
Patent registration for Redosemtide’s use in cartilage diseases in Korea is anticipated. No impact on the FY2027 July period; further disclosures will be notified as they arise.
Read more -
Fiscal Year Ending July 2026 Financial Summary
Announces the FY2026 July results overview and business development activities. Cash and deposits of 5.3 billion yen, annual expenditure around 1.6 billion yen, and R&D expenditure about 1.49 billion yen. No revenue recognition from operations, no milestone income or upfront...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥700
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
